| pubmed-article:12435813 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12435813 | lifeskim:mentions | umls-concept:C0013227 | lld:lifeskim |
| pubmed-article:12435813 | lifeskim:mentions | umls-concept:C1514559 | lld:lifeskim |
| pubmed-article:12435813 | lifeskim:mentions | umls-concept:C0033640 | lld:lifeskim |
| pubmed-article:12435813 | lifeskim:mentions | umls-concept:C0037903 | lld:lifeskim |
| pubmed-article:12435813 | lifeskim:mentions | umls-concept:C1545588 | lld:lifeskim |
| pubmed-article:12435813 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:12435813 | lifeskim:mentions | umls-concept:C1879547 | lld:lifeskim |
| pubmed-article:12435813 | pubmed:dateCreated | 2002-11-18 | lld:pubmed |
| pubmed-article:12435813 | pubmed:abstractText | Induction of apoptosis by chemotherapeutic drugs involves the sphingomyelin-ceramide (SM-CER) pathway. This signaling is critically dependent on reactive oxygen species (ROS) generation and p53/p56 Lyn activation. In this study, we have investigated the influence of protein kinase C (PKC) zeta overexpression on the SM-CER pathway in U937 human leukemia cell line. We show that PKCzeta overexpression resulted in delayed apoptosis and significant resistance to both 1-beta-D-arabinofuranosylcytosine (ara-C) and daunorubicin (DNR), but there was no significant protection against cell-permeant C(6)-CER. Moreover, PKCzeta overexpression abrogated drug-induced neutral sphingomyelinase stimulation and CER generation by inhibiting ROS production. We further investigated p53/p56 Lyn activation in PKCzeta-overexpressing U937 cells treated with ara-C or DNR. We demonstrate that PKCzeta inhibited p53/p56 Lyn phosphorylation and stimulation in drug- or H(2)O(2)-treated cells, suggesting that p53/p56 Lyn redox regulation is altered in PKCzeta-overexpressing cells. Finally, we show that PKCzeta-overexpressing U937 cells displayed accelerated H(2)O(2) detoxification. Altogether, our study provides evidence for the role of PKCzeta in the negative regulation of drug-induced SM-CER pathway. | lld:pubmed |
| pubmed-article:12435813 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12435813 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12435813 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12435813 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12435813 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12435813 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12435813 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12435813 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12435813 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12435813 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12435813 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12435813 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12435813 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12435813 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12435813 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12435813 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12435813 | pubmed:author | pubmed-author:GuyLaurentL | lld:pubmed |
| pubmed-article:12435813 | pubmed:author | pubmed-author:JaffrézouJean... | lld:pubmed |
| pubmed-article:12435813 | pubmed:author | pubmed-author:de... | lld:pubmed |
| pubmed-article:12435813 | pubmed:author | pubmed-author:Quillet-MaryA... | lld:pubmed |
| pubmed-article:12435813 | pubmed:author | pubmed-author:BezombesChris... | lld:pubmed |
| pubmed-article:12435813 | pubmed:author | pubmed-author:ApostolouAndr... | lld:pubmed |
| pubmed-article:12435813 | pubmed:author | pubmed-author:LouatThierryT | lld:pubmed |
| pubmed-article:12435813 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12435813 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12435813 | pubmed:pagination | 1446-55 | lld:pubmed |
| pubmed-article:12435813 | pubmed:dateRevised | 2011-11-2 | lld:pubmed |
| pubmed-article:12435813 | pubmed:articleTitle | Overexpression of protein kinase Czeta confers protection against antileukemic drugs by inhibiting the redox-dependent sphingomyelinase activation. | lld:pubmed |
| pubmed-article:12435813 | pubmed:affiliation | Institut National de la Santé et de la Recherche Médicale U563, Institut Claudius Regaud, Toulouse, France. christinebezombes@yahoo.com | lld:pubmed |
| entrez-gene:5590 | entrezgene:pubmed | pubmed-article:12435813 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:12435813 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12435813 | lld:pubmed |
